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Purpose: The goal of this study was to explore the perspectives and practice of radiation oncologists who treat
breast cancer patients who have had breast reconstruction.
Methods: In 2010, an original electronic survey was sent to all physician members of the American Society of
Radiation Oncology, National Cancer Research Institute-Breast Cancer Studies Group in the United Kingdom, Thai
Society of Therapeutic Radiology and Oncology, Swiss Society of Radiation Oncology, and Turkish Radiation
Oncology Society. We identified factors associated with radiation oncologists who treat breast cancer patients with
reconstruction performed prior to radiation and obtained information regarding radiation management of the
breast reconstruction.
Results: 358 radiation oncologists responded, and 60% of the physicians were from the United States. While 64%
of participants agree or strongly agree that breast image affects a woman’s quality of life during radiation, 57% feel
that reconstruction challenges their ability to deliver effective breast radiation. Compared with other countries,
treatment within the United States was associated with a high reconstruction rate (>/= 50% of mastectomy
patients) prior to radiation (p < 0.05). Delayed-immediate reconstruction with a temporary tissue expander was
more common in the United States than in other countries (52% vs. 23%, p = 0.01). Among physicians who treat
patients with tissue expanders, the majority (60%) prefer a moderately inflated implant with 150-250 cc of fluid
rather than a completely deflated (13%) or inflated expander (28%) during radiation. Among radiation oncologists
who treat reconstructions, 49% never use bolus and 40% never boost a breast reconstruction. United States
physicians were more likely than physicians from other countries to boost or bolus the reconstruction irrespective
of the type of reconstruction seen in their clinic patients (p < 0.01).
Conclusions: Great variation in practice is evident from our study of radiation treatment for breast cancer patients
with reconstruction. Further research on the impact and delivery of radiation to a reconstructed breast may validate
some of the observed practices, highlight the variability in treatment practice, and help create a treatment
consensus.
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Reconstruction following mastectomy for breast cancer
enhances a woman’s body image and psychological well-
being [1-3]. Although post-mastectomy radiation (PMRT)
significantly improves survival in patients with high risk
breast cancer [4-7], radiation to a reconstructed breast
may affect breast symmetry, impair long term cosmetic
outcome and potentially mitigate the life quality benefits
of reconstruction [8-12]. Indeed, several studies have
shown that PMRT may cause both short and long-term
reconstruction complications resulting in infection, pain,
poor wound healing, flap contraction, and implant extru-
sion [8,10,11,13,14]. Furthermore, previous research has
suggested that reconstruction may negatively impact
PMRT quality and delivery by increasing dose to the heart
and lungs and by impairing chestwall and regional nodal
coverage and overall outcome [15,16]. Given both the
potential benefits and risks of reconstruction, there
continues to be a significant amount of controversy
regarding breast reconstruction and radiation treatment.
Prospective data supporting the most optimal recon-
structive approach to women needing PMRT is lacking,
and within this context, there are a variety of institu-
tional preferences for the timing and type of reconstruc-
tion in breast cancer patients needing radiation. In
addition, recent surgical advances have increased the
number and complexity of reconstructive options avail-
able to women. Indeed, the impact of relatively novel re-
constructive devices, such as internal magnetic metallic
ports within temporary tissue expanders, on breast radi-
ation is only beginning to be explored [17,18]. Neverthe-
less, mastectomy patients today have the following
options: 1. No reconstruction, 2. Delayed reconstruction,
3. Delayed-immediate reconstruction with a temporary
tissue expander, 4. Immediate autologous tissue flap re-
construction with or without an implant, and 5. Skin
sparing mastectomy with or without preservation of the
nipple and immediate implant placement.
Currently, there is no consensus on how to optimally in-
corporate reconstruction and PMRT into the overall breast
cancer treatment plan. Moreover, there is no data
documenting existing radiation practice and preferences
based on clinic setting (academic vs. community), geo-
graphic locale, or the proportion of breast cancer patients
seen and treated. Using an original electronic survey ques-
tionnaire, the goals of this study were: 1) to identify factors
associated with radiation oncologists seeing a higher rate of
breast reconstruction prior to radiation among their breast
cancer patients and 2) to obtain information regarding radi-
ation management of the breast reconstruction.
Methods and materials
After obtaining Emory University Institutional Review
Board approval, a cover letter explaining the study purposeand survey instrument were sent via electronic mail to
physician members (including international members) of
the American Society of Radiation Oncology (ASTRO),
National Cancer Research Institute-Breast cancer Studies
Group in the United Kingdom, Thai Society of Therapeutic
Radiology and Oncology, Swiss Society of Radiation Oncol-
ogy and Turkish Radiation Oncology Society. Between
February and April 2010, the instrument was sent to po-
tential English-speaking participants three times using
Constant Contact Inc. Online Survey Service (Waltham,
MA). Physicians in training and/or who do not administer
radiation were asked to recuse themselves from participa-
tion. Eligible individuals wishing to participate provided
informed consent before taking part in the survey. Those
who responded to the survey could be distinguished from
those who did not, and therefore, only physicians who did
not reply were re-contacted for participation. Responses
could not be linked to specific individuals.
The questionnaire used in this study collected demo-
graphic information including clinic location by country,
practice type (academic vs. private practice), age, practi-
tioner gender, and the proportion of patients treated
with breast cancer following mastectomy with or with-
out reconstruction as well as the type of reconstruction.
The instrument also contained questions regarding
physician perceptions of reconstruction during radiation
and the ability to deliver effective radiation in this set-
ting. For these items (See Additional file 1), participants
were asked to rate their answers on a scale from 1 to 5
(1 = Strongly agree to 5 = Strongly Disagree). The other
questions are detailed in Additional file 2. As tissue
expanders with internal metallic ports are a relatively
novel advancement in reconstruction, the last set of
questions addressed specific considerations in planning
PMRT in women with tissue expanders.
Statistics
Descriptive statistics, including sample sizes and proportions,
were generated for all variables. To make comparisons
across reconstruction rate, we grouped physicians
whose mastectomy patients have a reconstructed breast
at least 50% of the time, as well as those whose patients
have a reconstructed breast less than 50% of the time.
We defined high volume breast cancer physicians as
those where breast cancer represented ≥ 50% of their
patient volume. Comparisons were also made across
regions; for example, Developed Countries (United
States of America (USA)/Canada/United Kingdom
(UK)/Western Europe/Australia) vs. Developing Countries
(Mexico/South America/Africa/Asia/Eastern Europe in-
cluding Turkey/Middle East), and USA vs. Europe
(Western), as the majority of respondents were from these
two regions. Gender and age (<50 vs. ≥50) comparisons
were also made. As all variables were categorical,
Table 1 Respondents’ radiation practice location by
country
Country N = 358 (%)
North America
United States of America 182 (60)
Canada 12 (4)
Mexico 3 (1)
South America
Argentina 2 (1)
Brazil 6 (2)
Chile 3 (1)
Europe
Western Europe
Austria 1 (0.3)
Belgium 2 (1)
France 3 (1)
Italy 3 (1)
Netherlands 7 (2)
Switzerland 2 (1)
United Kingdom 32 (11)
Eastern Europe
Poland 1 (0.3)
Macedonia 1 (0.3)
Turkey 18 (6)
Asia
China 1 (0.3)
India 2 (1)
Japan 1 (0.3)
Taiwan 2 (1)
Thailand 8 (3)
Middle East
Egypt 1 (0.3)
Iran 1 (0.3)
Israel 1 (0.3)
Jordan 1 (0.3)
Saudi Arabia 1 (0.3)
Africa
South Africa 3 (1)
Australia 1 (0.3)
New Zealand 1 (0.3)
Missing 56
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squared tests, with Fisher’s Exact Test used for smaller
sample sizes. Significance was assessed at the 0.05 level,
and the analysis was performed in SAS Version 9.3.
Results
Demographic characteristics of participating physicians
The survey was sent to 4753 physicians. 358 (8%) agreed
to participate. Each respondent’s clinic location by coun-
try is listed in Table 1. The majority of participating
physicians were from the USA (60%), between 30 and
49 years of age (64%), and identified themselves as
Caucasian (73%). More men (59%) than women (41%)
responded to the survey. 46% of respondents noted at
least half of their patients were individuals with breast
cancer. Of note, significantly more female than male
physicians had a high proportion of patients with breast
cancer (≥50%) (61% vs. 36%, p < 0.001).
Most participants (59%) stated that they work in
an academic or academically-affiliated center. 54% of
academically-affiliated vs. 46% non-academically-affiliated
of physicians noted that they practice with six or more
radiation oncologists (p = 0.40). More than half of the en-
rolled physicians (60%) serve an urban based patient
population. The majority of radiation oncologists (90%)
participate in a multidisciplinary breast tumor board, and
34% added that a reconstructive surgeon also attends their
tumor board conference. Other relevant provider and ra-
diation practice characteristics are shown in Table 2.
Provider perceptions regarding reconstruction and
radiation
Given 67% of respondents agree or strongly agree that
women are concerned about their breast appearance
during radiation, it was not surprising that 64% of
physicians also agree or strongly agree that breast image
during treatment affects a woman’s quality of life. How-
ever, while reconstruction improves body image, more
than half (57%) of participants believe that reconstruc-
tion challenges their ability to deliver effective breast
PMRT. Responses to these questions did not differ based
on physician gender or age. In addition, high volume
breast cancer physicians (50% or more of their patients
have breast cancer) were not more likely than others to
believe that reconstruction potentially effects the quality
of their radiation (54% vs. 60%, p = 0.3).
Mastectomy and reconstruction
Table 2 displays the proportion of breast cancer patients,
post mastectomy breast cancer patients, and patients
with reconstruction that participating physicians stated
they see in their radiation clinics. 98% of participating
radiation oncologists noted that at least one quarter of
their breast cancer patients have been treated withmastectomy (as opposed to breast conserving surgery)
when presenting for radiation. 82% of physicians stated
that at least 25% of these mastectomy patients have also
had breast reconstruction prior to radiation. A small, but
not insignificant, number of respondents (19%) noted
none of their mastectomy patients are reconstructed prior
to PMRT. However, a larger proportion of radiation
Table 2 Respondent practice characteristics
Characteristic N = 358 (%)
% of Patients with Breast Cancer
None 4 (1)
25% 152 (53)
50% 70 (24)
75% 45 (16)
100% 18 (6)
Missing 69
% of Breast Cancer Patients with Mastectomy
None 6 (2)
25% 217 (77)
50% 49 (17)
75% 10 (3.5)
100% 1 (0.4)
Missing 75
% of Breast Cancer Patients with Reconstruction
None 53 (19)
25% 154 (54)
50% 52 (18)
75% 24 (8)
100% 4 (1)
Missing 71
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patients are reconstructed before PMRT.
Potential factors associated with a higher mastectomy
rate (≥50% of breast cancer patients) among breast
cancer patients seen in the radiation clinic were then
evaluated. Mastectomy was more commonly seen by
participating radiation oncologists in developing rather
than developed nations (58% vs. 12%, p < 0.001).Table 3 Mastectomy and reconstruction in academically-affili
Characteristic A
% of Breast Cancer Patients with Mastectomy
None
25%
50%
75%
100%
Missing
% of Breast Cancer Patients with Reconstruction
None
25%
50%
75%
100%
MissingAcademically-affiliated centers were also more likely
than private/community radiation practices to see a high
proportion of post-mastectomy breast cancer patients
(≥50% of breast cancer patients) (28% vs. 12%, p = 0.001)
(See Table 3). Reconstructive surgery participation in
multidisciplinary tumor board conference was associated
with a low (<50% of breast cancer patients) rather than
high mastectomy rate (14% vs. 25%, p = 0.02). There
were no significant differences in mastectomy rate based
on population served (urban vs. small city/rural).
Factors potentially associated with a higher recon-
struction rate were also examined. Significantly more ra-
diation oncologists in developed countries treat a high
proportion of patients with reconstruction (≥50% of
mastectomy patients) than those in developing nations
(32% vs. 10%, p = 0.001). American radiation oncologists
were even more likely to treat reconstructions than their
European counterparts (40% vs. 9%, p < 0.001). There
were no significant differences in reconstruction rate
based on population served (urban vs. small city/rural),
practice type (academic vs. private practice), and recon-
structive surgeon participation in tumor board (yes vs. no).Reconstruction by type
Among radiation oncologists who treat breast reconstructions
(n = 234, See Table 4), the least common reconstruction
treated was permanent implant with almost half (43%)
of respondents stating that permanent implants are not
placed in their patients before PMRT. One quarter of
physicians also noted that autologous tissue flap
reconstructions are not performed in their patients be-
fore PMRT. Placement of a temporary tissue expander
appeared to be the most common form of reconstruc-
tion in women needing PMRT, as only 16% of radiationated and non-academically affiliated radiation centers
cademic N = 177 (%) Non-Academic N = 125 (%)
2 (1.2) 4 (3.3)
114 (70.8) 103 (84.4)
36 (22.4) 13 (10.7)
8 (5) 2 (1.6)
1 (0.6) 0 (0)
16 3
33 (20.0) 20 (16.4)
89 (53.9) 65 (53.3)
28 (17) 24 (19.7)
14 (8.5) 10 (8.2)
1 (0.6) 3 (2.5)
12 3
Table 4 Reconstruction types seen by radiation
oncologists who treat reconstructions
Reconstruction Type N = 234 (%)
% of Patients with Permanent Implant
None 101 (43.3)
25% 108 (46.4)
50% 16 (6.9)
75% 7 (3.0)
100% 1 (0.4)
Missing 1
% of Patients with Autologous Tissue Flaps
None 59 (25.4)
25% 133 (57.3)
50% 26 (11.2)
75% 10 (4.3)
100% 4 (1.7)
Missing 2
% of Patients with Temporary Tissue Expanders
None 38 (16.3)
25% 98 (42.1)
50% 37 (15.9)
75% 42 (18.0)
100% 18 (7.7)
Missing 1
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is not performed in their patients before treatment.
The country where the provider practiced was signifi-
cantly associated with the type of reconstruction
performed prior to PMRT. More American than European
radiation oncologists treated temporary tissue expanders
in 50% or more of their reconstructed patients (52% vs.
14%, p < 0.001), whereas more European than American
physicians treated autologous tissue flaps in this same10
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Figure 1 Use of bolus and boost by reconstruction type.proportion of patients (36% vs. 14%, p = 0.002). Radiation
oncologists who see a relatively high volume of breast can-
cer patients (50% or more of their patients) were not more
likely to see a specific type of reconstruction in their
patients.
Radiation treatment
Among the subset of respondents who treat reconstructions
with radiation (n = 234), almost half never use bolus
(49%) or boost (40%) the reconstructed breast. The
proportion of radiation oncologists who never treat the
reconstruction with bolus or boost was similar irre-
spective of the type of reconstruction typically seen
(≥25% of reconstructed breasts) by participating
physicians in their clinics (Figure 1). High volume
breast cancer radiation oncologists do not use bolus
(54% vs. 49%, p = 0.42) or prescribe boost dose to the
reconstruction (64% vs. 57%, p = 0.31) more frequently
than radiation oncologists who treat a lower volume of
breast cancer patients. The age of the participating
physicians was also not associated with whether or not
a patient with reconstruction was treated with bolus.
Physicians at least 50 years of age or older, however,
were more likely to prescribe boost dose than younger
physicians to the reconstruction (69% vs. 55%, p = 0.04).
There were no differences in the use of bolus or boost
to the reconstruction based on the gender of the
provider.
Based on the varying rates of reconstruction and
reconstruction types seen by radiation oncologists
worlwide, radiation treatment of the reconstruction was
examined based on geographic locale and only among
those providers who stated that they see reconstructed
breast cancer patients in their radiation centers.
Compared with physicians from other countries (n = 81),
American radiation oncologists (n = 152) treat more
reconstructions with bolus (62% vs. 24%, p < 0.001) and and Boost by
uction Type
nstruction Type
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struction (72% vs. 29%, p < 0.001) irrespective of recon-
struction type (See Figures 2 and 3).
In comparing physicians from the USA (n = 152) and
Europe (n = 36) specifically, more American than European
radiation oncologists use bolus (62% vs. 29%, p = 0.002)
and prescribe a boost dose (72% vs. 17%, p < 0.001) to the
reconstruction. However, when reconstruction type was
taken into account in the analysis, American radiation
oncologists were not more likely than European physicians
to administer bolus to a reconstructed breast with a per-
manent implant (58% vs. 40%, p = 0.20), but they were
more likely to give the permanent implant a boost dose
(76% vs. 20%, p < 0.001). In addition, Americans were still
more likely to bolus and boost the reconstruction than
Europeans if the reconstruction was an autologous tis-
sue flap (63% USA vs. 26% European physicians bolus;
74% USA vs. 16% European physicians boost) or tem-
porary tissue expander (62% USA vs. 26% European
physicians bolus; 74% USA vs. 17% European physicians
boost) (p < 0.01 for all comparisons).Tissue expanders
In the cohort of radiation oncologists who treat patients
with temporary tissue expander implants (n = 211), signifi-
cantly more physicians only treat patients with internal
rather than external ports (62% vs. 6%, p < 0.001) and sig-
nificantly more prefer an internal rather than external lo-
cation for access to the expander (85% vs. 15%, p < 0.001).
However, only 35% agree or strongly agree that the loca-
tion of the port affects radiation dose distribution and/or
challenges radiation treatment planning.40
50
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Figure 2 Use of bolus by reconstruction type and country.A small number of physicians (13%) prefer a com-
pletely deflated implant during radiation, while 28% pre-
fer a completely inflated implant during PMRT. The vast
majority of radiation oncologists (60%) prefer 150-250 cc
of fluid within the expander to facilitate PMRT planning.
Two thirds (66%) of physicians agreed or strongly agreed
that the volume of fluid within the implant affects radi-
ation dose distribution and can make radiation treatment
planning challenging, but only 47% of radiation
oncologists will ask reconstructive surgeons to adjust the
expander volume to 150-250 cc. Respondents who stated
that plastic surgeons attend their tumor board were more
likely to request tissue expander volume adjustments to
facilitate PMRT planning (45% vs. 32%, p = 0.07).
The most common reason for requesting a moderately
sized expander was to minimize dose to critical structures
including the heart and lungs (39%). Fewer radiation
oncologists (14%) will ask for adjustments in implant vol-
ume for the purposes of treating the internal mammary
lymph nodes. 91% of physicians stated that the laterality
(right vs. left) of the breast cancer did not affect their deci-
sion to request a moderately sized expander. Of note, in
patients with bilaterally reconstructed breasts with tem-
porary tissue expanders, 58% of physicians will request
that the implant volume be adjusted to 150–250 cc in the
contralateral non-cancerous breast to minimize radiation
dose to this unaffected breast. Treating a large proportion
of breast cancer patients (≥ 50% of patients) was not
associated with a preference for an internal or external
port, the approach to a tissue expander, or the reasons for
requesting a moderately sized implant. In addition, female
and male providers did not have significantly different
responses to these questions.Reconstruction Type 
 Country
** **
struction Type
* p<0.01
** p<0.001
40
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Figure 3 Use of boost by reconstruction type and country.
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Our study indicates great variation in both the rate and
type of reconstruction in breast cancer patients seen by
radiation oncologists. However, radiation oncologists
from developed nations see a larger proportion of their
breast cancer patients treated with reconstruction before
radiation than those from developing countries. More-
over, American respondents see more patients with
breast reconstruction than European physicians although
the relative number of participating European physicians
was small. While respondents from academic-affiliated
centers appeared to see more mastectomy patients than
non-academically affiliated centers, there was no signifi-
cant difference between the two groups in the propor-
tion of breast cancer patients who had undergone breast
reconstruction. Admittedly, the higher rate of mastectomy
patients seen among participating academic physicians is
likely due to differences in referral patterns with a higher
proportion of patients with advanced disease needing
mastectomy being seen and treated in academically-
affiliated centers.
American radiation oncologists more frequently
encountered patients with breast reconstruction in their
clinics and were more likely than others to use bolus
and/or boost the reconstruction. Placement of a tempor-
ary tissue expander was the most common form of re-
construction seen by respondents, and Americans were
more likely than others to see this reconstruction type.
As providers who treat tissue expanders may be more
apt to bolus or boost a tissue expander than an autolo-
gous tissue flap, analysis was performed taking into
account reconstruction type. There was no difference in
radiation management based on reconstruction type.
Americans were still more likely than others to boost orbolus any form of reconstruction (permanent implant,
autologous tissue flap, or temporary tissue expander).
Moreover, American physicians were more likely than
European physicians to boost or bolus an autologous
tissue flap or temporary tissue expander. This finding is
consistent with the observation that American physicians
are also more likely than Europeans to use bolus in post-
mastectomy patients without reconstruction [19].
Nevertheless, our data indicate that less than half of
American physicians, (albeit significantly more than
European physicians), will bolus and/or boost the chestwall
when a reconstruction is present. Randomized trials of
boost and bolus in the post-mastectomy setting are lacking,
but current practice suggests that reconstructed breast
cancer patients are often treated without bolus and to a
lower total dose than mastectomy-only patients due to
concerns over complications and cosmetic outcome. Com-
mon indications for using bolus and/or boost (e.g. close
or positive margins, skin involvement by the tumor,
and tumor size), however, presumably exist in both
reconstructed and non-reconstructed patients. Future
prospective studies examining long term outcomes are
needed to determine if bolus and/or boost provide a re-
currence free benefit and evaluate whether the observed
current radiation practice in women with reconstruction
is potentially impairing long term cancer control.
Although physicians agree that reconstruction may
improve the life quality of a patient during radiation,
most radiation oncologists in this study feel that recon-
struction also challenges their ability to deliver effective
treatment. Tissue expanders may provide some com-
promise although patients are inconvenienced by a sec-
ond major surgical procedure for permanent implant
placement and potential complications [8,10,17]. Tissue
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have a breast mound whose volume may be adjusted to
minimize its impact on radiation quality. Indeed, a num-
ber of providers feel that decreasing the size of the ex-
pander to 150 to 250 cc from a fully expanded implant
improves radiation treatment and delivery by decreasing
dose to the heart and lung. However, less than half of ra-
diation providers will ask reconstructive surgeons to
adjust the volume within an expander suggesting that ei-
ther institutional protocols regarding expander volume
may already be in place or that communication between
radiation oncologists and reconstructive surgeons could
be improved. Others have also noted that earlier inclu-
sion of radiation oncologists in the overall treatment
planning process of the patient may influence patient
decisions regarding surgical treatment and could pos-
sibly influence a patient’s choice to undergo reconstruc-
tion [20]. Indeed, a multidisciplinary tumor board may
function as a venue for improved communication be-
tween providers, and our data seems to support this no-
tion, as respondents who stated that reconstructive
surgeons attend their tumor board were more likely to
ask for tissue expander volumes to be adjusted to facili-
tate radiation treatment planning.
Limitations of this study include a low overall response
rate and the possibility that information reported by the
participating radiation oncologists does not truly repre-
sent their practice. Nevertheless, surveys have been used
previously to more broadly understand the scope of
practice within various medical fields including radiation
oncology [20-22]. This questionnaire was not formally
validated and was only sent three times to potential
participants, which may have contributed to the rela-
tively small number of participating physicians. It is also
likely that physicians who do not treat breast cancer
were also less likely to respond to the survey limiting the
potential number of respondents. As most of the
participants were members of ASTRO and the instru-
ment was written only in English, our findings
emphasize the perspectives of English speaking
physicians who are mostly American. Furthermore, will-
ing participants may have had a greater interest in radi-
ation and reconstruction due to frequent experience
with reconstruction in their patients. Therefore, the
study results could be biased to reflect the views of
physicians frequently encountering reconstruction al-
though an effort was made to assess respondents based
on the rate of reconstruction seen among breast cancer
patients in their radiation center. Results regarding treat-
ment of the reconstruction were purposely limited to ra-
diation oncologists who see patients with breast
reconstruction to determine the current practice of
those physicians, as data regarding radiation manage-
ment of breast reconstruction is lacking. The study wasadmittedly limited to radiation society membership lists
and e-mail addresses to which we had access, resulting
in poor response rates from physicians located in South
America, Asia, and Africa.
This small study, however, represents the first attempt
to document and establish a baseline of practice
regarding reconstruction and the radiation approach to
reconstruction in physicians from multiple countries.
Prospective research on the impact and delivery of radi-
ation to a reconstructed breast is needed to validate the
observed practice and aid in creating a generalized treat-
ment consensus.
Conclusions
Collectively, findings from this study suggest that there
continue to be a variety of approaches to radiation treat-
ment of a reconstructed breast following mastectomy.
Among the respondents, the most common form of re-
construction in patients presenting for radiation was
placement of a temporary tissue expander. However, when
treating a reconstruction, many radiation oncologists will
not use bolus or boost the reconstruction regardless of re-
construction type.
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